Table 3.

Adjusted outcome analyses according to treatment strategy

		RD for OS at 5 y, %			RD for PFS at 5 y, %			RD for TFS at 5 y, %
Training cohort	Variable	RD	95% CI	P	RD	95% CI	P	RD	95% CI	P
All	MR	8	1 to 15	.019	15	7 to 24	<.001	10	3 to 17	.007
	FLIPI
	Low	—	—	—	—	—	—	—	—	—
	Intermediate	−1	−11 to 8	NS	4	−9 to 18	NS	2	−9 to 13	NS
	High	−11	−20 to −2	.016	−14	−26 to −2	.023	−8	−18 to 2	NS
	Bulk	−4	−10 to 3	NS	−10	−18 to −1	.025	−5	−12 to 2	NS
	FL grade 3A	−4	−12 to 4	NS	−3	−14 to 7	NS	−4	−13 to 4	NS
	+Anthracycline	4	−3 to 11	NS	9	−1 to 18	NS	7	−1 to 15	NS
	Female sex	0	−6 to 7	NS	4	−4 to 13	NS	4	−3 to 11	NS
R-CHOP/CHOP-like	MR	10	1 to 20	.049	23	10 to 35	<.001	12	1 to 23	.028
	FLIPI
	Low	—	—	—	—	—	—	—	—	—
	Intermediate	2	−13 to 17	NS	8	−11 to 27	NS	4	−13 to 20	NS
	High	−7	−20 to 7	NS	−18	−36 to −1	.048	−5	−20 to 10	NS
	Bulk	0	−11 to 10	NS	−7	−21 to 7	NS	−5	−17 to 6	NS
	FL grade 3A	−2	−12 to 8	NS	0	−13 to 14	NS	−5	−16 to 7	NS
	Female sex	−3	−13 to 8	NS	4	−9 to 17	NS	3	−8 to 14	NS
R-CVP/CVP-like	MR	7	−3 to 17	NS	11	−2 to 24	NS	10	−1 to 21	NS
	FLIPI
	Low	—	—	—	—	—	—	—	—	—
	Intermediate	−2	−15 to 12	NS	5	−16 to 25	NS	1	−14 to 17	NS
	High	−16	−30 to −2	.025	−18	−37 to 1	NS	−14	−29 to 1	NS
	Bulk	−6	−16 to 3	NS	−11	−23 to 2	NS	−5	−16 to 5	NS
	FL grade 3A	−4	−18 to 11	NS	−8	−27 to 11	NS	−4	−20 to 11	NS
	Female sex	4	−6 to 13	NS	7	−6 to 20	NS	9	−2 to 20	NS

Pseudo values approach, nonproportional hazards. Bold values represent significant P values (P < .05).